Twinbeech Capital LP Allakos Inc. Transaction History

Twinbeech Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $63,697 - $150,423	-24,499 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $90,357 - $174,490	-17,787 Reduced 42.06%	24,499 $140,000
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $361,545 - $4.73 Million	42,286 New	42,286 $414,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.